Previous 10 | Next 10 |
2024-01-29 08:15:00 ET Like many of the biotechs pursuing coronavirus vaccine development, Novavax (NASDAQ: NVAX) has seen better days. Its shares are down by 96% over the past three years, and the company's remaining shareholders face fading hopes for a spontaneous revival. Non...
2024-01-28 07:25:00 ET Novavax (NASDAQ: NVAX) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's investigational vaccine -- then plummeted 98% from their peak as the vacci...
2024-01-23 09:13:00 ET Novavax (NASDAQ: NVAX) soared more than 2,700% early in the pandemic as investors bet on its ability to bring a coronavirus vaccine to market. The company followed through on that -- but not as quickly as planned. Novavax's product launched more than a year af...
2024-01-15 14:21:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following last year’s big rally, the stock market is off to a slow start in 2024. After two weeks the S&P 500 index is essentially flat. That’s not enough time to make a t...
2024-01-09 13:35:18 ET Novavax, Inc. (NVAX) JPMorgan 42nd Annual Healthcare Conference January 08, 2024, 08:15 PM ET Company Participants John Jacobs - President and CEO John Trizzino - Chief Commercial Officer & Chief Business Officer James Kelly - CFO F...
2024-01-04 13:51:02 ET More on BioNTech, Moderna, etc. Pfizer: If You Missed The Pandemic Entry, Here's Another Chance BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovatio...
Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
2023-12-28 15:21:17 ET More on Novavax Novavax: Do Not Expect A Turnaround In 2024 Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference (Transcript) Novavax: Less Is Less - Shrinking COVID Market Takes Its Toll (Rating Downgrade) JN.1 Omicr...
2023-12-27 02:55:50 ET Summary Novavax faces major challenges in 2024, including a significant Gavi dispute and going concern issues. Recent financial results show declining revenues and cash reserves, with a high operational cash burn rate. Market sentiment is cautious, with ...
News, Short Squeeze, Breakout and More Instantly...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he still can't recommend Twilio (NASDAQ:TWLO). On June 14, Morgan Stan...
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profi...
Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine PR Newswire Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine w...